



(11) **EP 2 308 465 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/00 (2006.01) **A61M 31/00 (2006.01)**

(48) Corrigendum issued on:
19.11.2014 Bulletin 2014/47

(45) Date of publication and mention
of the grant of the patent:
23.07.2014 Bulletin 2014/30

(21) Application number: **10187041.8**

(22) Date of filing: **08.10.2010**

(54) **Transmucosal drug delivery device and method including chemical permeation enhancers**

Vorrichtung zur transmukosalen Arzneimittelverabreichung und Verfahren mit chemischen Permeationsförderern

Dispositif d'administration transmucosale de médicament et procédé incluant des activateurs de la perméation chimique

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **08.10.2009 US 576087**

(43) Date of publication of application:
13.04.2011 Bulletin 2011/15

(73) Proprietor: **Palo Alto Research Center**
Incorporated
Palo Alto, California 94304 (US)

(72) Inventors:
• **Uhland, Scott**
San Jose, CA 95125 (US)
• **Peeters, Eric**
Mountain View, CA 94043 (US)
• **Fatakawala, Hussain**
North Brunswick, NJ 08902 (US)

(74) Representative: **Jones, Helen M.M.**
Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES (GB)

(56) References cited:
WO-A1-01/12101 **WO-A1-97/41831**
WO-A2-2005/089728 **DE-A1- 4 130 843**
US-A- 5 415 629 **US-A- 6 086 909**
US-A1- 2003 219 472 **US-A1- 2004 082 937**

- **Hussain Fatakawala ET AL: "Hydrogen peroxide mediated transvaginal drug delivery", International Journal of Pharmaceutics, vol. 409, no. 1-2, 1 May 2011 (2011-05-01) , pages 121-127, XP55036809, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2011.02.052**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).